Single- or dual-antiplatelet therapy after transcatheter aortic valve replacement: A protocol of systematic review and meta-analysis. Issue 6 (12th February 2021)

• Record Type: Journal Article
• Authors: Li, Hongyan; Wang, Yafeng; Li, Longyu; Dan, Bao
• Is Part Of: Medicine. Volume 100:Issue 6(2021)
• Publication Date: 2021-02-12
• Subjects: dual-antiplatelet therapy (DAPT) -- meta-analyses -- randomized controlled trials -- single-antiplatelet therapy (SAPT) -- systematic review -- transcatheter aortic valve replacement (TAVR); Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000024550
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: The evidence related to bleeding and thromboembolic events after transcatheter aortic valve replacement (TAVR) compared single antiplatelet therapy (SAPT) with dual antiplatelet therapy (DAPT) treatment are inconsistent. Moreover, there are some limitations such as small sample size and the risk of bias in existing studies. We will conduct a comprehensive systematic review and meta-analysis to explore the safety and efficacy of SAPT or DAPT after TAVR. Methods: A comprehensive literature search of PubMed, EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials will be searched to retrieve studies involving SAPT versus DAPT after TAVR. Two investigators will independently select studies, extract data, and assess the quality of the included study. Any disagreement will be resolved by the third investigator. The study will use a random-effects model to pool the results of all studies and use the relative risk and 95% confidence intervals to summarize individual trial outcomes and estimate pooled effect. The study will use the Grading of Recommendations Assessment, Development, and Evaluation to assess the certainty of evidence. Results: This study will provide high-quality evidence for treatment of TAVR in terms of effectiveness and safety. Conclusion: This systematic review aims to provide evidence for treatment of TAVR in different antiplatelet therapies. Registration: The systematic review and meta-analysis is registered in the OSF REGISTRIES (10.17605/OSF.IO/Q42TE) international prospective register.